Larotaxel

Larotaxel: An Experimental Taxane Drug[edit | edit source]

Larotaxel (also known by its code names XRP9881 and RPR109881) is a chemotherapeutic agent that belongs to the taxane class of drugs. Derived and refined for potential antineoplastic applications, Larotaxel showcases the characteristic mechanisms and properties inherent to taxanes, with a unique chemical profile distinguishing it from its contemporaries.

Taxane Class Overview[edit | edit source]

Taxanes are a class of diterpenes originally isolated from the bark of the Pacific yew tree, Taxus brevifolia. Their chemotherapeutic properties are primarily based on their ability to:

Stabilize microtubule polymers.
Prevent depolymerization, hindering cell division and proliferation^[1].

Prominent members of the taxane class include:

Paclitaxel (Taxol): The pioneering taxane drug with significant clinical efficacy^[2].
Docetaxel (Taxotere): A semi-synthetic analogue of paclitaxel with an improved efficacy-toxicity ratio in certain cancers^[3].

Larotaxel: Distinct Features[edit | edit source]

Distinct from paclitaxel and docetaxel, Larotaxel boasts a specific chemical structure that may result in a unique pharmacodynamic and pharmacokinetic profile. However, as with many experimental drugs, extensive research is pivotal to elucidate the spectrum of its antitumor activities and potential side effects^[4].

Clinical Evaluation & Applications[edit | edit source]

Larotaxel has been subjected to experimental evaluations for its:

Mechanism of action in cell lines.
Efficacy in various tumor models.
Safety and tolerability in early-phase clinical trials.

Though its precise position in oncological therapeutics has not been fully established, preliminary investigations suggest potential utility in a spectrum of malignancies resistant to other taxane therapies^[5].

Conclusion[edit | edit source]

Larotaxel encapsulates the ongoing efforts of researchers to optimize the therapeutic potential of taxanes, aiming to overcome the limitations of the first-generation agents. While it remains under investigation, Larotaxel's unique profile underscores the dynamic and evolving landscape of oncology drug development.

References[edit | edit source]

↑ Horwitz, S.B. (1994). Mechanism of action of taxol. Trends in Pharmacological Sciences, 15(5), 134-136.
↑ Rowinsky, E.K., et al. (1990). Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. Journal of Clinical Oncology, 8(12), 2010-2025.
↑ Tannock, I.F., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502-1512.
↑ Bissery, M.C., et al. (1995). Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Research, 55(11), 2325-2333.
↑ Vrignaud, P., et al. (1998). Preclinical profile of XRP9881 (RPR 109881A), a novel taxane, and its activity in taxane-resistant cell lines. Anti-Cancer Drugs, 9(9), 759-771.

Larotaxel Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.